The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...

Patients with differentiated thyroid cancer treated with the GLP-1s showed no increased risk of recurrence over a more than 5 ...

Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability ...

LOS ANGELES--(BUSINESS WIRE)--The inaugural Stephenson Global Prize was awarded to Dr. Frank McCormick, a pioneering scientist whose discoveries have transformed the understanding of RAS-driven ...

Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response ...

Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care ...

Obesity is a public health problem that can increase an individual's risk of many other disorders... | Cell And Molecular Biology ...

The agency also expanded approval of a recombinant von Willebrand factor product (Vonvendi) to include routine prophylaxis in ...